Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Heparan sulfate (HS) is an important component of the extracellular matrix and cell surface, which plays a key role in cell-cell and cell-matrix interactions. Functional activity of HS directly depends on its structure, which determined by a complex system of HS biosynthetic enzymes. During malignant transformation, the system can undergo significant changes, but for
glioma
, HS biosynthesis has not been studied in detail. In this study, we performed a comparative analysis of the HS biosynthetic system in human gliomas of different grades. RT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (
EXT1
,
EXT2
,
NDST1
,
NDST2
,
GLCE
,
HS2ST1
,
HS3ST1
,
HS3ST2
,
HS6ST1
,
HS6ST2
,
SULF1
,
SULF2
,
HPSE
) was decreased by 1.5-2-fold in Grade II-III
glioma
(
p
< 0.01) and by 3-fold in Grade IV
glioma
(glioblastoma multiforme, GBM) (
p
< 0.05), as compared with the para-tumourous tissue. The inhibition was mainly due to the elongation (a decrease in
EXT1/2
expression by 3-4-fold) and 6-
O
-sulfation steps (a decrease in
6OST1/2
expression by 2-5-fold) of the HS biosynthesis. Heparanase (
HPSE
) expression was identified in 50% of GBM tumours by immunostaining, and was characterised by a high intratumoural heterogeneity of the presence of the HPSE protein. The detected disorganisation of the HS biosynthetic system in gliomas might be a potential molecular mechanism for the changes of HS structure and content in tumour microenvironments, contributing to the invasion of
glioma
cells and the development of the disease.
...
PMID:Heparan Sulfate Biosynthetic System Is Inhibited in Human Glioma Due to EXT1/2 and HS6ST1/2 Down-Regulation. 2910 77